Philadelphia – A refined version of CAR-T cell therapy, designed to spare healthy B-cells from immune attack, shows promise in improving treatment tolerability for lymphoma patients and potentially offering benefits for those with systemic lupus erythematosus. Researchers at the University of Pennsylvania unveiled the CART4-34 therapy in Science Translational Medicine in 2026, building upon their pioneering function in CAR-T cell therapy against CD19.
The development represents a significant step forward in personalized cancer treatment and autoimmune disease management. CAR-T cell therapy, a revolutionary approach, genetically modifies a patient’s own T-cells to target and destroy cancer cells. This groundbreaking technique, initially developed to combat B-cell lymphomas and leukemias, has offered hope to patients who haven’t responded to conventional treatments. However, a common side effect of traditional CAR-T therapy targeting CD19 is B-cell aplasia – the depletion of all B-cells, including those crucial for a healthy immune system. This leaves patients vulnerable to infections and necessitates long-term immunoglobulin replacement therapy.
The team, led by Carl June, MD, at the University of Pennsylvania, addressed this challenge by engineering CAR-T cells that target a different antigen, CART4-34, found on malignant B-cells but largely absent from healthy B-cells. This precision targeting aims to eliminate cancer cells while preserving the patient’s ability to produce antibodies and maintain a robust immune response. According to the study published in Science Translational Medicine, the CART4-34 therapy demonstrated encouraging results in early clinical trials, showing effective tumor control with significantly less impact on healthy B-cell populations. DOI: 10.1126/scitranslmed.adr9382
The Evolution of CAR-T Cell Therapy
Carl June, a Richard W. Vague Professor in Immunotherapy at the Perelman School of Medicine at the University of Pennsylvania and director of the Center for Cellular Immunotherapies (CCI) at Penn Medicine’s Abramson Cancer Center, is widely recognized as a pioneer in the field of CAR-T cell therapy. His work, spanning decades, has fundamentally changed the landscape of cancer treatment. The June Lab at Penn Medicine details his contributions to immunotherapy.
The initial breakthrough came with the development of CAR-T cells targeting CD19, a protein found on the surface of many B-cell malignancies. These engineered T-cells, equipped with a chimeric antigen receptor (CAR), effectively seek out and destroy cancer cells expressing CD19. The CAR is a synthetic molecule comprised of an extracellular target binding module, a transmembrane module and an intracellular signaling module. The incorporation of co-stimulatory properties within the antigen receptor itself proved to be a critical advance. This approach, first demonstrated in clinical trials in the early 2010s, achieved remarkable remission rates in patients with advanced leukemia and lymphoma who had exhausted all other treatment options. Penn Medicine News highlights this pivotal moment in cancer treatment.
However, the success of CD19-targeted CAR-T therapy wasn’t without its challenges. As mentioned, B-cell aplasia emerged as a significant side effect, requiring ongoing immunoglobulin replacement therapy to prevent infections. The therapy can sometimes trigger cytokine release syndrome (CRS), a potentially life-threatening inflammatory response. Researchers have been actively working to mitigate these side effects through various strategies, including refined CAR designs, improved patient selection criteria, and more effective supportive care measures.
CART4-34: A More Targeted Approach
The CART4-34 therapy represents a significant refinement of the CAR-T cell approach. By targeting an antigen that is more selectively expressed on malignant B-cells, the therapy aims to minimize the collateral damage to healthy B-cells. This targeted approach could potentially reduce the necessitate for immunoglobulin replacement therapy and improve the long-term immune function of patients undergoing CAR-T cell treatment. The principle behind this innovation extends beyond hematologic malignancies; researchers are exploring the genetic engineering of other cell types, such as macrophages, NK cells, and CIK cells, to target a wider range of cancers. Further details on this research are available from the June Lab.
Beyond its potential in lymphoma treatment, the CART4-34 therapy is similarly being investigated for its efficacy in systemic lupus erythematosus (SLE), an autoimmune disease characterized by chronic inflammation and immune system dysfunction. In SLE, the immune system mistakenly attacks the body’s own tissues, leading to a wide range of symptoms. The CART4-34 therapy aims to selectively eliminate autoreactive B-cells – those that produce antibodies that attack the body’s own cells – thereby reducing inflammation and disease activity. The potential for CAR-T therapy to address autoimmune diseases represents a paradigm shift in the treatment of these complex conditions.
Expanding the Reach of CAR-T Cell Therapy
The success of CAR-T cell therapy has spurred a wave of research and development efforts aimed at expanding its application to other cancers, including solid tumors. Solid tumors pose a greater challenge than blood cancers due to their complex microenvironment and the difficulty of T-cells in penetrating the tumor mass. Researchers are exploring various strategies to overcome these obstacles, including engineering CAR-T cells with enhanced trafficking capabilities, combining CAR-T therapy with other immunotherapies, and developing CAR-T cells that target multiple antigens simultaneously.
Carl June’s contributions to the field have been widely recognized. He was named a winner of the 2024 Breakthrough Prize in Life Sciences for his pioneering work in CAR T-cell therapy. He also received the 2025 Balzan Prize for Gene and Gene-Modified Cell Therapy, acknowledging his invention and development of a genetically modified cellular therapy that has cured patients with fatal hematological malignancies. The University of Pennsylvania’s website provides more information on these accolades.
Looking Ahead
The development of CART4-34 therapy and ongoing research into CAR-T cell therapy represent a beacon of hope for patients battling cancer and autoimmune diseases. While challenges remain, the progress made in recent years is remarkable. The ability to harness the power of the immune system to fight disease is transforming the landscape of medicine, offering the potential for more effective and personalized treatments.
The next steps for CART4-34 therapy involve larger clinical trials to confirm its efficacy and safety in a broader patient population. Researchers will also continue to refine the therapy to further minimize side effects and optimize its effectiveness. The ongoing research at the University of Pennsylvania and other leading institutions around the world promises to unlock even more potential for CAR-T cell therapy in the years to come.
Key Takeaways:
- CART4-34 therapy is a refined CAR-T cell approach designed to spare healthy B-cells.
- The therapy shows promise in treating lymphoma and potentially systemic lupus erythematosus.
- Carl June, MD, is a pioneer in CAR-T cell therapy and has received numerous awards for his work.
- Ongoing research aims to expand the application of CAR-T therapy to other cancers, including solid tumors.
The future of cancer and autoimmune disease treatment is being actively shaped by innovations like CART4-34. Stay informed about the latest developments in immunotherapy and personalized medicine by following reputable sources like the National Cancer Institute and the National Institute of Allergy and Infectious Diseases. What are your thoughts on the potential of CAR-T cell therapy? Share your comments below, and please share this article with your network.
Keep reading